8-氧杂-5-氮杂螺[3.5]壬烷 | 602326-48-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 中文名称: 8-氧杂-5-氮杂螺[3.5]壬烷
• 中文别名: 8-噁-5-氮杂螺[3.5]壬烷
• 英文名称: 8-oxa-5-azaspiro[3.5]nonane
• CAS: 602326-48-7
• 化学式: C₇H₁₃NO
• mdl: MFCD17170792
• 分子量: 127.186
• InChiKey: QJWGZYJFBDSKHF-UHFFFAOYSA-N

物化性质

• 沸点：
  207.2±15.0 °C(Predicted)
• 密度：
  1.04±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  21.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  (5-(6-methyl-3-(1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-ylamino)isothiazol-3-yl)methyl methanesulfonate 、 8-氧杂-5-氮杂螺[3.5]壬烷 在 N,N-二异丙基乙胺 、 sodium iodide 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 N-[6-methyl-3-(1H-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-3-(8-oxa-5-azaspiro[3.5]nonan-5-ylmethyl)-1,2-thiazol-5-amine
  参考文献：
  名称：

  Discovery of orally bioavailable imidazo[1,2-a]pyrazine-based Aurora kinase inhibitors

  摘要：

  We report a series of potent imidazo[1,2-a]pyrazine-based Aurora kinase inhibitors. Optimization of the solvent accessible 8-position led to improvements in both oral bioavailability and off-target kinase inhibition. Compound 25 demonstrates anti-tumor activity in an A2780 ovarian tumor xenograft model. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.08.140

文献信息

• [EN] ANTIDIABETIC BICYCLIC COMPOUNDS<br/>[FR] COMPOSÉS BICYCLIQUES ANTIDIABÉTIQUES
  申请人：MERCK SHARP & DOHME

  公开号：WO2016022742A1

  公开（公告）日：2016-02-11

  Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.

  结构式（I）的新化合物及其药用盐是G蛋白偶联受体40（GPR40）的激动剂，可能对通过G蛋白偶联受体40介导的疾病的治疗、预防和抑制具有用处。本发明的化合物可能对2型糖尿病的治疗有用，以及对常与该疾病相关的疾病，包括肥胖和脂质紊乱，如混合型或糖尿病性脂质代谢异常、高脂血症、高胆固醇血症和高甘油三酯血症的治疗有用。
• [EN] 6-HETEROCYCLYL-4-MORPHOLIN-4-YLPYRIDINE-2-ONE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER AND DIABETES<br/>[FR] COMPOSÉS 6-HÉTÉROCYCLYL-4-MORPHOLIN-4-YLPYRIDINE-2-ONE UTILISÉS POUR LE TRAITEMENT DU CANCER ET DU DIABÈTE
  申请人：SPRINT BIOSCIENCE AB

  公开号：WO2017140843A1

  公开（公告）日：2017-08-24

  The invention provides novel 6-heterocyclyl-4-morpholin-4-yl-pyridine-2-one compounds of formula (I), pharmaceutical compositions containing such compounds, and methods for using such compounds in treatment of diseases including cancer, diabetes, inflammatory disease, neurodegenerative disorders, cardiovascular disorders and viral infections; wherein R1, R2, R3 and A are as defined in the specification.

  该发明提供了公式（I）的新型6-杂环基-4-吗啡啉-4-基吡啶-2-酮化合物，包含该化合物的药物组合物，以及使用该化合物治疗癌症、糖尿病、炎症性疾病、神经退行性疾病、心血管疾病和病毒感染等疾病的方法；其中R1、R2、R3和A如规范中所定义。
• USE OF SUBSTITUTED 1-(ARYL ETHYNYL)-, 1-(HETEROARYL ETHYNYL)-, 1-(HETEROCYCLYL ETHYNYL)- AND 1-(CYCLOALKENYL ETHYNYL)-CYCLOHEXANOLS AS ACTIVE AGENTS AGAINST ABIOTIC PLANT STRESS
  申请人：BAYER CROPSCIENCE AG

  公开号：US20150305334A1

  公开（公告）日：2015-10-29

  The invention relates to the use of substituted 1-(arylethynyl)-, 1-(heteroarylethynyl)-, 1-(heterocyclylethynyl)- and 1-(cycloalkenylethynyl)cyclohexanols or salts thereof where the radicals in the general formula (I) correspond to the definitions given in the description, for enhancing stress tolerance in plants to abiotic stress and/or for increasing plant yield.

  本发明涉及使用取代的1-(芳基乙炔基)-、1-(杂芳基乙炔基)-、1-(杂环基乙炔基)-和1-(环烯基乙炔基)环己醇或其盐，其中通式(I)中的基团与描述中给定的定义相对应，用于增强植物对非生物胁迫的耐受性和/或增加植物产量。
• [EN] MONOBACTAMS AND METHODS OF THEIR SYNTHESIS AND USE<br/>[FR] MONOBACTAMES ET PROCÉDÉS DE SYNTHÈSE ET D'UTILISATION DE CES DERNIERS
  申请人：HARVARD COLLEGE

  公开号：WO2015103583A1

  公开（公告）日：2015-07-09

  Described herein are monobactam antibiotics of Formula (I), (Ι'), (II), and (II'), along with methods and intermediates for preparing these compounds. Pharmaceutical compositions and methods of treating infectious diseases using the monobactams are also provided.

  本文描述了单环内酰胺抗生素的化学式(I)、(Ι')、(II)和(II')，以及制备这些化合物的方法和中间体。还提供了使用单环内酰胺治疗传染病的药物组合物和方法。
• [EN] PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS<br/>[FR] PYRAZOLOTHIAZOLE CARBOXAMIDES ET LEURS UTILISATIONS EN TANT QU'INHIBITEURS DE PDGFR
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2022136509A1

  公开（公告）日：2022-06-30

  The disclosure is directed to compounds of formula (I),and pharmaceutically acceptable salts thereof. Pharmaceutical compositions comprising compounds of formula (I), as well as methods of their use and preparation, are also described.

  本公开涉及式(I)的化合物及其药学上可接受的盐。还描述了包含式(I)化合物的制药组合物，以及它们的使用和制备方法。